Philadelphia-based Chimeron Bio, an RNA company developing self-amplifying RNA vaccines and therapeutics, recently entered into a manufacturing agreement with FUJIFILM Diosynth Biotechnologies (FDB), a subsidiary of FUJIFILM Corporation, to advance its oncology portfolio.
“We selected FUJIFILM Diosynth Biotechnologies as our manufacturing partner because of their proven track record in the advanced therapies space,” Chimeron Bio CEO Jolly Mazumdar said. “FDB really understands our ChaESAR™ platform and pipeline potential, making them the best partner to scale up our processes and help bring our ground-breaking approach for the treatment of underserved patients closer to reality.”
Chimeron Bio selected FUJIFILM Diosynth Biotechnologies as a partner for the transfer and scale-up of Chimeron’s drug substance manufacturing process. Manufacturing will occur at FUJIFILM Diosynth Biotechnologies’ manufacturing facility in Texas.
Materials from this partnership will help facilitate Chimeron’s Investigational New Drug-enabling work.
“Chimeron’s ChaESAR platform has the potential to impact how we bring treatments and therapies to patients,” Gerry Farrell, CEO of the FUJIFILM Diosynth Biotechnologies Texas site, said. “We are delighted to be the partner of choice to bring their technology into our (good manufacturing practices) facility and produce Bulk Drug Substance to support their clinical trials.”
The ChaESAR platform is a self-assembling biosynthetic nonlipid nanoparticle.